Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBT Margin (2017 - 2026)

Organogenesis Holdings has reported EBT Margin over the past 9 years, most recently at 28.11% for Q4 2025.

  • For Q4 2025, EBT Margin rose 2002.0% year-over-year to 28.11%; the TTM value through Dec 2025 reached 8.33%, up 891.0%, while the annual FY2025 figure was 8.33%, 891.0% up from the prior year.
  • EBT Margin for Q4 2025 was 28.11% at Organogenesis Holdings, up from 14.03% in the prior quarter.
  • Over five years, EBT Margin peaked at 28.11% in Q4 2025 and troughed at 29.74% in Q1 2025.
  • A 5-year average of 3.88% and a median of 7.31% in 2022 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: surged 3626bps in 2021 and later crashed -2579bps in 2025.
  • Year by year, EBT Margin stood at 14.77% in 2021, then tumbled by -49bps to 7.58% in 2022, then plummeted by -124bps to 1.8% in 2023, then skyrocketed by 549bps to 8.1% in 2024, then surged by 247bps to 28.11% in 2025.
  • Business Quant data shows EBT Margin for ORGO at 28.11% in Q4 2025, 14.03% in Q3 2025, and 11.72% in Q2 2025.